Frater, J, Ewer, KJ, Ogbe, A, Pace, M, Adele, S, Adland, E, Alagaratnam, J, Aley, PK, Ali, M, Ansari, MA, Bara, A, Bittaye, M, Broadhead, S, Brown, A, Brown, H, Cappuccini, F, Cooney, E, Dejnirattisai, W, Dold, C, Fairhead, C et al, Fok, H, Folegatti, PM, Fowler, J, Gibbs, C, Goodman, AL, Jenkin, D, Jones, M, Makinson, R, Marchevsky, NG, Mujadidi, YF, Nguyen, H, Parolini, L, Petersen, C, Plested, E, Pollock, KM, Ramasamy, MN, Rhead, S, Robinson, H, Robinson, N, Rongkard, P, Ryan, F, Serrano, S, Tipoe, T, Voysey, M, Waters, A, Zacharopoulou, P, Barnes, E, Dunachie, S, Goulder, P, Klenerman, P, Screaton, GR, Winston, A, Hill, AVS, Gilbert, SC, Pollard, AJ, Fidler, S, Fox, J, Lambe, T, Oxford COVID Vaccine Trial Group, and Tahmasebi, F (2021) Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. The lancet. HIV, 8 (8). e474-e485. ISSN 2405-4704